ロード中...
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them,...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
PAGEPress Publications
2009
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3222244/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/hr.2009.e4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|